Raj Chovatiya, MD, PhD, MSCI

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.

Raj Chovatiya, MD, PhD, MSCI, actually said symptoms "never" lie so, particularly in patients with skin of color, if skin signs aren't clear, ask about the patient's experience.

AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.

Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.

AAD 2025: Chovatiya discusses whether melanin concentration plays a role in skin physiology and cautioned against typing with factors that are not true biologic constructs.

Chovatiya, expert clinical dermatologist and researcher, points out that the term "skin of color" comprises a heterogenous set of topics, in an interview at AAD 2025.